NICE does not recommend erlotinib as maintenance treatment after chemotherapy that contains platinum for people with locally advanced or metastatic non-small-cell lung cancer. Maintenance treatment is sometimes used by people whose cancer did not worsen immediately after having chemotherapy (which is also known as stable disease).

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life if they meet certain criteria. It was not certain whether erlotinib provides enough benefit to patients to justify its high cost and it did not qualify for special consideration, so NICE did not recommend it.

  • National Institute for Health and Care Excellence (NICE) accreditation logo